Literature DB >> 15789346

Post-translational processing of beta-secretase in Alzheimer's disease.

Christina Sidera1, Richard Parsons, Brian Austen.   

Abstract

Beta-amyloid is released into the brains of Alzheimer's patients, where it aggregates and causes damage to neurons. It is cleaved proteolytically from a large transmembrane glycoprotein amyloid precursor protein by a membrane-bound protease, known as beta-secretase identified previously as the acid protease, Asp-2. We have shown previously that beta-secretase is up-regulated by increased intracellular cholesterol, and down-regulated by cholesterol biosynthesis inhibition. Here we show using mass spectrometry that discrete changes in the glycosylation and palmitoylation of beta-secretase occur when cells expressing it are treated with statins.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15789346     DOI: 10.1002/pmic.200401185

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  8 in total

1.  Statins inhibit the dimerization of beta-secretase via both isoprenoid- and cholesterol-mediated mechanisms.

Authors:  Richard B Parsons; Gemma C Price; Joanna K Farrant; Daryl Subramaniam; Jubril Adeagbo-Sheikh; Brian M Austen
Journal:  Biochem J       Date:  2006-10-15       Impact factor: 3.857

2.  Spatial and temporal control of age-related APP processing in genomic-based beta-secretase transgenic mice.

Authors:  Matthew J Chiocco; Bruce T Lamb
Journal:  Neurobiol Aging       Date:  2006-01-18       Impact factor: 4.673

3.  Altered palmitoylation and neuropathological deficits in mice lacking HIP14.

Authors:  Roshni R Singaraja; Kun Huang; Shaun S Sanders; Austen J Milnerwood; Rochelle Hines; Jason P Lerch; Sonia Franciosi; Renaldo C Drisdel; Kuljeet Vaid; Fiona B Young; Crystal Doty; Junmei Wan; Nagat Bissada; R Mark Henkelman; William N Green; Nicholas G Davis; Lynn A Raymond; Michael R Hayden
Journal:  Hum Mol Genet       Date:  2011-07-20       Impact factor: 6.150

4.  Palmitoylation of nicotinic acetylcholine receptors.

Authors:  J K Alexander; A P Govind; R C Drisdel; M P Blanton; Y Vallejo; T T Lam; W N Green
Journal:  J Mol Neurosci       Date:  2009-08-20       Impact factor: 3.444

Review 5.  Mechanisms of disease: new therapeutic strategies for Alzheimer's disease--targeting APP processing in lipid rafts.

Authors:  Haipeng Cheng; Kulandaivelu S Vetrivel; Ping Gong; Xavier Meckler; Angèle Parent; Gopal Thinakaran
Journal:  Nat Clin Pract Neurol       Date:  2007-07

6.  Low levels of human HIP14 are sufficient to rescue neuropathological, behavioural, and enzymatic defects due to loss of murine HIP14 in Hip14-/- mice.

Authors:  Fiona B Young; Sonia Franciosi; Amanda Spreeuw; Yu Deng; Shaun Sanders; Natalie C M Tam; Kun Huang; Roshni R Singaraja; Weining Zhang; Nagat Bissada; Chris Kay; Michael R Hayden
Journal:  PLoS One       Date:  2012-05-23       Impact factor: 3.240

7.  Beta-amyloid impairs reelin signaling.

Authors:  Inmaculada Cuchillo-Ibáñez; Valeria Balmaceda; Arancha Botella-López; Alberto Rabano; Jesus Avila; Javier Sáez-Valero
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

8.  Post-Translational Modifications of BACE1 in Alzheimer's Disease.

Authors:  Wen Wen; Ping Li; Panwang Liu; Shijun Xu; Fushun Wang; Jason H Huang
Journal:  Curr Neuropharmacol       Date:  2022       Impact factor: 7.708

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.